Repotrectinib Trial for Advanced Tumors

This study explores a drug called repotrectinib for patients with advanced solid tumors, which are a type of cancer that has spread or cannot be surgically removed. Some tumors have changes in specific genes known as ALK, ROS1, or NTRK1-3. The study aims to find the best dose of repotrectinib and how well it works in these patients.

Phase 1 is to determine the safe dosage, while Phase 2 will look at how the drug affects the tumor's size and progression. The study is divided into groups based on the type of tumor gene changes and previous treatments.

• Participants need to be at least 12 years old and have a specific type of tumor gene change.
• The study will last several months and involves taking medication and regular health check-ups.
• There might be risks, including side effects from the drug.

Participants must not be in another trial and should not have serious heart problems or active infections. Eligibility also depends on specific health criteria.